Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization

Molecular Endocrinology

Volumn 22, Issue 10, 2008, Pages 2278-2292

  Grant, Michael ^a,b   Alturaihi, Haydar ^a   Jaquet, Philippe ^c   Collier, Brian ^b   Kumar, Ujendra ^a,d  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c TIMONE HOSPITAL   (France)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; BETA ARRESTIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; L 779976; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 5; UNCLASSIFIED DRUG;

ARTICLE; CELL FUNCTION; CELL GROWTH; COMPARATIVE STUDY; CONTROLLED STUDY; DIMERIZATION; DRUG INHIBITION; EMBRYO; GROWTH INHIBITION; HUMAN; HUMAN CELL; HYPOPHYSIS TUMOR; INTERNALIZATION; KINETICS; MODULATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN MODIFICATION;

ARRESTINS; CELL LINE; CELL PROLIFERATION; DIMERIZATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GTP-BINDING PROTEINS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PROTEIN STRUCTURE, QUATERNARY; RECEPTORS, SOMATOSTATIN; SIGNAL TRANSDUCTION;

EID: 52949103344     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2007-0334     Document Type: Article

References (64)

1. Patel YC 1999 Somatostatin and its receptor family. Front Neuroendocrinol 20:157-198
2. Moller LN, Stidsen CE, Hartmann B, Holst JJ 2003 Somatostatin receptors. Biochim Biophys Acta 1616:1-84
3. Lamberts SW, de Herder WW, Hofland LJ 2002 Somatostatin analogs in the diagnosis and treatment of cancer. Trends Endocrinol Metab 13:451-457
4. Tichomirowa MA, Daly AF, Beckers A 2005 Treatment of pituitary tumors: somatostatin. Endocrine 28:93-100
5. Bevan JS 2005 The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 90:1856-1863
6. Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D, Barkan A 2005 A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 90:4405-4410
7. Ferrante E, Pellegrini C, Bondioni S, Peverelli E, Locatelli M, Gelmini P, Luciani P, Peri A, Mantovani G, Bosari S, Beck-Peccoz P, Spada A, Lania A 2006 Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocr Relat Cancer 13:955-962
8. Zatelli MC, Piccin D, Ambrosio MR, Bondanelli M, degli Uberti EC 2006 Antiproliferative effects of somatostatin analogs in pituitary adenomas. Pituitary 9:27-34
9. Resmini E, Dadati P, Ravetti JL, Zona G, Spaziante R, Saveanu A, Jaquet P, Culler MD, Bianchi F, Rebora A, Minuto F, Ferone D 2007 Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. J Clin Endocrinol Metab 92:1592-1599
10. Hofland LJ, Lamberts SW 2003 The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 24:28-47
11. Jaquet P, Saveanu A, Gunz G, Fina F, Zamora AJ, Grino M, Culler MD, Moreau JP, Enjalbert A, Ouafik LH 2000 Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. J Clin Endocrinol Metab 85:781-792
12. Park C, Yang I, Woo J, Kim S, Kim J, Kim Y, Sohn S, Kim E, Lee M, Park H, Jung J, Park S 2004 Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous SRIF activity and response to octreotide. Endocr J 51:227-236
13. Sharif N, Gendron L, Wowchuk J, Sarret P, Mazella J, Beaudet A, Stroh T 2007 Coexpression of somatostatin receptor subtype 5 affects internalization and trafficking of somatostatin receptor subtype 2. Endocrinology 148:2095-2105
14. Terrillon S, Bouvier M 2004 Roles of G-protein-coupled receptor dimerization. EMBO Rep 5:30-34
15. Prinster SC, Hague C, Hall RA 2005 Heterodimerization of G protein-coupled receptors: specificity and functional significance. Pharmacol Rev 57:289-298
16. AbdAlla S, Lother H, el Massiery A, Quitterer U 2001 Increased AT1 receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med 7:1003-1009
17. AbdAlla S, Lother H, Langer A, el Faramawy Y, Quitterer U 2004 Factor XIIIA transglutaminase crosslinks AT1 receptor dimers of monocytes at the onset of atherosclerosis. Cell 119:343-354
18. Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC, Patel YC 2000 Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem 275:7862-7869
19. Patel RC, Kumar U, Lamb DC, Eid JS, Rocheville M, Grant M, Rani A, Hazlett T, Patel SC, Gratton E, Patel YC 2002 Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells. Proc Natl Acad Sci USA 99:3294-3299
20. Grant M, Patel RC, Kumar U 2004 The role of subtype-specific ligand binding and the C-tail domain in dimer formation of human somatostatin receptors. J Biol Chem 279:38636-38643
21. Grant M, Collier B, Kumar U 2004 Agonist-dependent dissociation of human somatostatin receptor 2 dimers: a role in receptor trafficking. J Biol Chem 279:36179-36183
22. Patel RC, Lange DC, Patel YC 2002 Photobleaching fluorescence resonance energy transfer reveals ligand-induced oligomer formation of human somatostatin receptor subtypes. Methods 27:340-348
23. Tsao P, Cao T, von Zastrow M 2001 Role of endocytosis in mediating downregulation of G-protein-coupled receptors. Trends Pharmacol Sci 22:91-96
24. Lefkowitz RJ, Shenoy SK 2005 Transduction of receptor signals by β-arrestins. Science 308:512-517
25. Tulipano G, Stumm R, Pfeiffer M, Kreienkamp HJ, Hollt V, Schulz S 2004 Differential β-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes. J Biol Chem 279:21374-21382
26. Waldhoer M, Fong J, Jones RM, Lunzer MM, Sharma SK, Kostenis E, Portoghese PS, Whistler JL 2005 A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc Natl Acad Sci USA 102:9050-9055
27. McGraw DW, Mihlbachler KA, Schwarb MR, Rahman FF, Small KM, Almoosa KF, Liggett SB 2006 Airway smooth muscle prostaglandin-EP1 receptors directly modulate β2-adrenergic receptors within a unique heterodimeric complex. J Clin Invest 116:1400-1409
28. Pello OM, Martinez-Munoz L, Parrillas V, Serrano A, Rodriguez-Frade JM, Toro MJ, Lucas P, Monterrubio M, Martinez AC, Mellado M 2008 Ligand stabilization of CXCR4/δ-opioid receptor heterodimers reveals a mechanism for immune response regulation. Eur J Immunol 38:537-549
29. Pages P, Benali N, Saint-Laurent N, Esteve JP, Schally AV, Tkaczuk J, Vaysse N, Susini C, Buscail L 1999 sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of SHP-1. J Biol Chem 274:15186-15193
30. Lahlou H, Saint-Laurent N, Esteve JP, Eychene A, Pradayrol L, Pyronnet S, Susini C 2003 sst2 somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation. J Biol Chem 278:39356-39371
31. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ 1996 Octreotide. N Engl J Med 334:246-254
32. de Herder WW, Hofland LJ, van der Lely AJ, Lamberts SW 2003 Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr Relat Cancer 10:451-458
33. Ballare E, Persani L, Lania AG, Filopanti M, Giammona E, Corbetta S, Mantovani S, Arosio M, Beck-Peccoz P, Faglia G, Spada A 2001 Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J Clin Endocrinol Metab 86:3809-3814
34. Ren SG, Taylor J, Dong J, Yu R, Culler MD, Melmed S 2003 Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion. J Clin Endocrinol Metab 88:4239-4245
35. Ben-Shlomo A, Wawrowsky KA, Proekt I, Wolkenfeld NM, Ren SG, Taylor J, Culler MD, Melmed S 2005 Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion. J Biol Chem 280:24011-24021
36. Duran-Prado M, Bucharles C, Gonzalez BJ, Vazquez-Martinez R, Martinez-Fuentes AJ, Garcia-Navarro S, Rhodes SJ, Vaudry H, Malagon MM, Castano JP 2007 Porcine somatostatin receptor 2 displays typical pharmacological sst2 features but unique dynamics of homodimerization and internalization. Endocrinology 148:411-421
37. Gines S, Hillion J, Torvinen M, Le Crom S, Casado V, Canela EI, Rondin S, Lew JY, Watson S, Zoli M, Agnati LF, Verniera P, Lluis C, Ferre S, Fuxe K, Franco R 2000 Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. Proc Natl Acad Sci USA 97:8606-8611
38. Mellado M, Rodriguez-Frade JM, Vila-Coro AJ, Fernandez S, Martin de Ana A, Jones DR, Toran JL, Martinez AC 2001 Chemokine receptor homo- or heterodimerization activates distinct signaling pathways. EMBO J 20:2497-2507
39. Yoshioka K, Saitoh O, Nakata H 2002 Agonist-promoted heteromeric oligomerization between adenosine A1 and P2Y1 receptors in living cells. FEBS Lett 523:147-151
40. Rodriguez-Frade JM, del Real G, Serrano A, Hernanz-Falcon P, Soriano SF, Vila-Coro AJ, de Ana AM, Lucas P, Prieto I, Martinez AC, Mellado M 2004 Blocking HIV-1 infection via CCR5 and CXCR4 receptors by acting in trans on the CCR2 chemokine receptor. EMBO J 23:66-76
41. Kearn CS, Blake-Palmer K, Daniel E, Mackie K, Glass M 2005 Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Mol Pharmacol 67:1697-1704
42. Jiang H, Betancourt L, Smith RG 2006 Ghrelin amplifies dopamine signaling by cross talk involving formation of growth hormone secretagogue receptor/dopamine receptor subtype 1 heterodimers. Mol Endocrinol 20:1772-1785
43. Hukovic N, Panetta R, Kumar U, Rocheville M, Patel YC 1998 The cytoplasmic tail of the human somatostatin receptor type 5 is crucial for interaction with adenylyl cyclase and in mediating desensitization and internalization. J Biol Chem 273:21416-21422
44. Hukovic N, Rocheville M, Kumar U, Sasi R, Khare S, Patel YC 1999 Agonist-dependent up-regulation of human somatostatin receptor type 1 requires molecular signals in the cytoplasmic C-tail. J Biol Chem 274:24550-24558
45. Stroh T, Jackson AC, Sarret P, Dal Farra C, Vincent JP, Kreienkamp HJ, Mazella J, Beaudet A 2000 Intracellular dynamics of sst5 receptors in transfected COS-7 cells: maintenance of cell surface receptors during ligand-induced endocytosis. Endocrinology 141:354-365
46. Terrillon S, Barberis C, Bouvier M 2004 Heterodimerization of V1a and V2 vasopressin receptors determines the interaction with β-arrestin and their trafficking patterns. Proc Natl Acad Sci USA 101:1548-1553
47. Perron A, Sharif N, Sarret P, Stroh T, Beaudet A 2007 NTS2 modulates the intracellular distribution and trafficking of NTS1 via heterodimerization. Biochem Biophys Res Commun 353:582-590
48. Lavoie C, Mercier JF, Salahpour A, Umapathy D, Breit A, Villeneuve LR, Zhu WZ, Xiao RP, Lakatta EG, Bouvier M, Hebert TE 2002 β1/β2- Adrenergic receptor heterodimerization regulates β2-adrenergic receptor internalization and ERK signaling efficacy. J Biol Chem 277:35402-35410
49. Qian X, Jin L, Grande JP, Lloyd RV 1996 Transforming growth factor-β and p27 expression in pituitary cells. Endocrinology 137:3051-3060
50. Qian X, Jin L, Kulig E, Lloyd RV 1998 DNA methylation regulates p27kip1 expression in rodent pituitary cell lines. Am J Pathol 153:1475-1482
51. Takeuchi S, Koeffler HP, Hinton DR, Miyoshi I, Melmed S, Shimon I 1998 Mutation and expression analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in pituitary tumors. J Endocrinol 157:337-341
52. Lidhar K, Korbonits M, Jordan S, Khalimova Z, Kaltsas G, Lu X, Clayton RN, Jenkins PJ, Monson JP, Besser GM, Lowe DG, Grossman AB 1999 Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors. J Clin Endocrinol Metab 84:3823-3830
53. Bamberger CM, Fehn M, Bamberger AM, Ludecke DK, Beil FU, Saeger W, Schulte HM 1999 Reduced expression levels of the cell-cycle inhibitor p27Kip1 in human pituitary adenomas. Eur J Endocrinol 140:250-255
54. Korbonits M, Chahal HS, Kaltsas G, Jordan S, Urmanova Y, Khalimova Z, Harris PE, Farrell WE, Claret FX, Grossman AB 2002 Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. J Clin Endocrinol Metab 87:2635-2643
55. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC 2000 Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288:154-157
56. AbdAlla S, Lother H, Quitterer U 2000 AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature 407:94-98
57. Scarselli M, Novi F, Schallmach E, Lin R, Baragli A, Colzi A, Griffon N, Corsini GU, Sokoloff P, Levenson R, Vogel Z, Maggio R 2001 D2/D3 dopamine receptor heterodimers exhibit unique functional properties. J Biol Chem 276:30308-30314
58. Yoshioka K, Saitoh O, Nakata H 2001 Heteromeric association creates a P2Y-like adenosine receptor. Proc Natl Acad Sci USA 98:7617-7622
59. Gomes I, Gupta A, Filipovska J, Szeto HH, Pintar JE, Devi LA 2004 A role for heterodimerization of μ and δ opiate receptors in enhancing morphine analgesia. Proc Natl Acad Sci USA 101:5135-5139
60. Zhu WZ, Chakir K, Zhang S, Yang D, Lavoie C, Bouvier M, Hebert TE, Lakatta EG, Cheng H, Xiao RP 2005 Heterodimerization of β1- and β2-adrenergic receptor subtypes optimizes β-adrenergic modulation of cardiac contractility. Circ Res 97:244-251
61. Bockaert J, Fagni L, Dumuis A, Marin P 2004 GPCR interacting proteins (GIP). Pharmacol Ther 103:203-221
62. 2A. J Biol Chem 276:14027-14036
63. Law PY, Erickson-Herbrandson LJ, Zha QQ, Solberg J, Chu J, Sarre A, Loh HH 2005 Heterodimerization of μ-and δ-opioid receptors occurs at the cell surface only and requires receptor-G protein interactions. J Biol Chem 280:11152-11164
64. Rohrer SP, Birzin ET, Mosley RT, Berk SC, Hutchins SM, Shen DM, Xiong Y, Hayes EC, Parmar RM, Foor F, Mitra SW, Degrado SJ, Shu M, Klopp JM, Cai SJ, Blake A, Chan WW, Pasternak A, Yang L, Patchett AA, Smith RG, Chapman KT, Schaeffer JM 1998 Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 282:737-740